Evidence map›Paper›PMID 25412506›Full record

SynthesisPLoS neglected tropical diseases2014

Approaches to refining estimates of global burden and economics of dengue.

Donald S Shepard, Eduardo A Undurraga, Miguel Betancourt-Cravioto, María G Guzmán, Scott B Halstead, Eva Harris, Rose Nani Mudin, Kristy O Murray, Roberto Tapia-Conyer, Duane J Gubler

Abstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Analysis of dengue fever disease in West Africa.Experimental biology and medicine (Maywood, N.J.) · 2023
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Current Trends and Limitations in Dengue Antiviral Research.Tropical medicine and infectious disease · 2021
    Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Donald S ShepardSchneider Institutes for Health Policy, Heller School, Brandeis University, Waltham, Massachusetts, United States of America.
Eduardo A UndurragaSchneider Institutes for Health Policy, Heller School, Brandeis University, Waltham, Massachusetts, United States of America.
Miguel Betancourt-CraviotoCarlos Slim Health Institute, Mexico City, Mexico.
María G GuzmánPedro Kourí Tropical Medicine Institute, Havana, Cuba.
Scott B HalsteadDengue Vaccine Initiative, Rockville, Maryland, United States of America.
Eva HarrisUniversity of California, Berkeley, California, United States of America.
Rose Nani MudinMinistry of Health, Putrajaya, Malaysia.
Kristy O MurrayBaylor College of Medicine and Texas Children's Hospital, Houston, Texas, United States of America.
Roberto Tapia-ConyerCarlos Slim Health Institute, Mexico City, Mexico.
Duane J GublerDuke-NUS Graduate Medical School, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue presents a formidable and growing global economic and disease burden, with around half the world's population estimated to be at risk of infection. There is wide variation and substantial uncertainty in current estimates of dengue disease burden and, consequently, on economic burden estimates. Dengue disease varies across time, geography and persons affected. Variations in the transmission of four different viruses and interactions among vector density and host's immune status, age, pre-existing medical conditions, all contribute to the disease's complexity. This systematic review aims to identify and examine estimates of dengue disease burden and costs, discuss major sources of uncertainty, and suggest next steps to improve estimates. Economic analysis of dengue is mainly concerned with costs of illness, particularly in estimating total episodes of symptomatic dengue. However, national dengue disease reporting systems show a great diversity in design and implementation, hindering accurate global estimates of dengue episodes and country comparisons. A combination of immediate, short-, and long-term strategies could substantially improve estimates of disease and, consequently, of economic burden of dengue. Suggestions for immediate implementation include refining analysis of currently available data to adjust reported episodes and expanding data collection in empirical studies, such as documenting the number of ambulatory visits before and after hospitalization and including breakdowns by age. Short-term recommendations include merging multiple data sources, such as cohort and surveillance data to evaluate the accuracy of reporting rates (by health sector, treatment, severity, etc.), and using covariates to extrapolate dengue incidence to locations with no or limited reporting. Long-term efforts aim at strengthening capacity to document dengue transmission using serological methods to systematically analyze and relate to epidemiologic data. As promising tools for diagnosis, vaccination, vector control, and treatment are being developed, these recommended steps should improve objective, systematic measures of dengue burden to strengthen health policy decisions.

Indexed as

Cost of IllnessCosts and Cost AnalysisDengueGlobal HealthHealth Care CostsHumans

Identifiers

PMID25412506
PMCPMC4238988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.